Tactical Therapeuticsinca Delaware Corp Formed In 2005Has Developed A Patented Cancer Therapeuticcarboxyamidotriazole Orotatecto As An Orphan Drug To Treat Glioblastomagbm Malignant Gliomasbrain Metastases And Different Types Of Resistant Solid Cancers With Different Mutationsthe Business Model Is Virtual With Full Time Ceo And Part Time Management Teamand Highly Distinguished And Experienced Scientific Advisors And Consultantssome Since 2005 Company Strategy Is To Carry Our Tasks For Which Expertise Is Available Inhouseand To Outsource Rest To Qualified Expert Service Providerse Gpre Clinical And Clinical Work Has Been Outsourced To Highly Reputable Clinical Research Organizationsclinical Manufacturing Organizationsand Regulatory Consultants The Intellectual Property Comprises 8 Issued United States Patents And 75 International Patents Lasting Through 2040 This Work Has Been Done Inhousecompetitive Advantagesthe Clinical Development Program For Gbm And Other Brain Cancers Has Compelling Competitive Advantages Cto Has Differentiated Against Other Drugsit Is Oralsafecrosses The Blood Brain Barriershows Efficacyand Overcomes Resistance Closely Monitoring Phase I Ii Iii Trials Listed In Clinicaltrials Govseveral Phase Iii Trials Have Failed And Been Stopped For Not Meeting Clinical Endpoints Cto Offers Unique Value Propositionsince Randomized Phase Ii Trials Are Designed For Fast Track Approvalin 2025 Tactical Therapeutics Is Seeking A Strategic Partner To Participate In The Development And Commercialization Of The Company S Lead Productcto
